The U.S. Food and Drug Administration approved an expanded peripheral artery disease indication for Janssen’s Xarelto (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization due to symptomatic PAD.
The common over-the-counter drug aspirin might be the key to finding a viable treatment method for breast cancer.
The Janssen Pharmaceutical Companies of Johnson & Johnson presented data from the Phase 3 VOYAGER PAD study which showed Xarelto (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization compared to aspirin alone regardless of whether it was the first, second, third or subsequent event.
The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.
The National Institutes of Health launched two of the three late-stage clinical trials to test the effectiveness and safety of different types of blood thinners in treating Covid-19 among adults.
AstraZeneca released positive data from the Phase III THALES trial of Brilinta (ticagrelor) used twice a day with an aspirin.
The U.S. Food and Drug Administration approved AstraZeneca Plc’ drug for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints.
For people without heart disease, taking a daily aspirin to prevent heart attacks and strokes may increase the risk of severe brain bleeding to the point where it outweighs any potential benefit, a research review suggests.
